Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias

Journal of Alzheimer's Disease

Volumn 50, Issue 2, 2016, Pages 539-546

  Morenas Rodríguez, Estrella ^a,b   Cervera Carles, Laura ^a,b   Vilaplana, Eduard ^a,b   Alcolea, Daniel ^a,b   Carmona Iragui, María ^a,b   Dols Icardo, Oriol ^a,b   Ribosa Nogué, Roser ^a,b   Muñoz Llahuna, Laia ^a,b   Sala, Isabel ^a,b   Belen Sanchez Saudinos M ^a,b   Blesa, Rafael ^a,b   Clarimón, Jordi ^a,b   Fortea, Juan ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; amyloid ; biomarker; cerebrospinal fluid; dementia; plasma; progranulin; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PROGRANULIN; TAU PROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN; AMYLOID BETA PROTEIN; GRN PROTEIN, HUMAN; SIGNAL PEPTIDE;

AGED; ALZHEIMER DISEASE; APOE EPSILON4 GENE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE; GENETIC POLYMORPHISM; GRN GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; DEMENTIA; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS;

EID: 84970934198     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150746     Document Type: Article

References (40)

1. Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G. (2012). Progranulin: A proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem 287, 32298-32306
2. Nguyen AD, Nguyen TA, Martens LH, Mitic LL, FareseRVJr. (2013). Progranulin: At the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab 24, 597-606
3. Toh H, Chitramuthu BP, Bennett HP, Bateman A. (2011). Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci 45, 538-548
4. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W. (2008). Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181, 37-41
5. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919
6. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924
7. Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, Snowden JS, Mann DM. (2007). Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TARDNA-binding protein, TDP-43. Acta Neuropathol 113, 521-533
8. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133
9. Cruts M, Van Broeckhoven C. (2008). Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet 24, 186-194
10. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R. (2009). Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583-591
11. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. (2008). Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235-1239
12. Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R, De Deyn PP, Robberecht W, Van Broeckhoven C. (2009). Serum biomarker for progranulinassociated frontotemporal lobar degeneration. Ann Neurol 65, 603-609
13. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peeters K, Schymkowitz J, Rousseau F, Martin JJ, Cruts M, De Deyn PP, Van Broeckhoven C. (2008). Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71, 656-664
14. Hsiung GY, Fok A, Feldman HH, Rademakers R, Mackenzie IR. (2011). rs5848 polymorphism and serum progranulin level. J Neurol Sci 300, 28-32
15. Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL, Rosen H, Rabinovici G. (2013). Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 70, 774-778
16. Sheng J, Su L, Xu Z, Chen G. (2014). Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease. Gene 542, 141-145
17. Viswanathan J, Makinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M. (2009). An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet 150B, 747-750
18. Kamalainen A, Viswanathan J, Natunen T, Helisalmi S, Kauppinen T, Pikkarainen M, Pursiheimo JP, Alafuzoff I, Kivipelto M, Haapasalo A, Soininen H, Herukka SK, Hiltunen M. (2013). GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J Alzheimers Dis 33, 23-27
19. Hosokawa M, Arai T, Masuda-Suzukake M, Kondo H, Matsuwaki T, Nishihara M, Hasegawa M, Akiyama H. (2015). Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol 74, 158-165
20. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV Jr, Gan L. (2014). Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat Med 20, 1157-1164
21. Nicholson AM, Finch NA, Thomas CS, Wojtas A, Rutherford NJ, Mielke MM, Roberts RO, Boeve BF, Knopman DS, Petersen RC, Rademakers R. (2014). Progranulin protein levels are differently regulated in plasma and CSF. Neurology 82, 1871-1878
22. Alcolea D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, Antunez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigue M, Guisasola MC, Sanchez Ruiz D, Marin Munoz J, Calero M, Blesa R, Clarimon J, Carmona-Iragui M, Morenas-Rodriguez E, Rodriguez-Rodriguez E, Vazquez Higuera JL, Fortea J, Lleo A. (2015). Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85, 626-633
23. Sala I, Belen Sanchez-Saudinos M, Molina-Porcel L, Lazaro E, Gich I, Clarimon J, Blanco-Vaca F, Blesa R, Gomez-Isla T, Lleo A. (2008). Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord 26, 506-512
24. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269
26. Costa S, Suarez-Calvet M, Anton S, Dols-Icardo O, Clarimon J, Alcolea D, Fortea J, Carmona M, Sala I, Sanchez-Saudinos MB, Blesa R, Lleo A. (2013). Comparison of 2 diagnostic criteria for the behavioral variant of frontotemporal dementia. Am J Alzheimers Dis Other Demen 28, 469-476
27. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477
28. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. (2011). Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014
29. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. (1996). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47, 1-9
30. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496-503
31. Dols-Icardo O, Suarez-Calvet M, Hernandez I, Amer G, Anton-Aguirre S, Alcolea D, Fortea J, Boada M, Tarraga L, Blesa R, Lleo A, Clarimon J. (2012). Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiol Aging 33, 1851.e1817-1859
32. Alcolea D, Carmona-Iragui M, Suarez-Calvet M, Sanchez-Saudinos MB, Sala I, Anton-Aguirre S, Blesa R, Clarimon J, Fortea J, Lleo A. (2014). Relationship between beta-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 42, 157-167
33. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleo A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schroder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K. (2013). CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261
34. Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sanchez-Saudinos MB, Sala I, Anton-Aguirre S, Gonzalez S, Medrano S, Pegueroles J, Morenas E, Clarimon J, Blesa R, Lleo A. (2014). Cerebrospinal fluid beta-Amyloid and phospho-Tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol 76, 223-230
35. Guardia-Laguarta C, Pera M, Clarimon J, Molinuevo JL, Sanchez-Valle R, Llado A, Coma M, Gomez-Isla T, Blesa R, Ferrer I, Lleo A. (2010). Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J Neuropathol Exp Neurol 69, 53-59
36. Vercellino M, Grifoni S, Romagnolo A, Masera S, Mattioda A, Trebini C, Chiavazza C, Caligiana L, Capello E, Mancardi GL, Giobbe D, Mutani R, Giordana MT, Cavalla P. (2011). Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult Scler 17, 1194-1201
37. Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. (2013). Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 70, 78-84
38. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C. (2014). TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6, 243ra286
39. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM. (2010). YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912
40. Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O. (2013). Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 5, 9